



**Jusmiral Holdings Limited**  
Globe House  
Ground & First Floors  
23 Kennedy Avenue  
1075 Nicosia - Cyprus  
Tel: +357 22007960

7 April 2026

**To**  
**The Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400001**

**Scrip Code: 543064**

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India**  
**Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400051**  
**Scrip Symbol: COHANCE**

Dear Sir/Madam,

**Sub: Declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011 (“SEBI Takeover Regulations”)**

Pursuant to Regulation 31(4) of the SEBI Takeover Regulations, we, Jusmiral Holdings Limited, promoter of Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited), along with following persons acting in concert with Jusmiral Holdings Limited i.e., Berhyanda Limited (Promoter), Jusmiral Midco Limited, hereby declare that we have not made any encumbrance on the shares of Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited), directly or indirectly, other than those already disclosed during the financial year 2025-26.

This is for your information and record.

Thanking you,  
Yours faithfully,  
**For Jusmiral Holdings Limited**

A handwritten signature in black ink, appearing to read 'CPs', is written over a horizontal line.

Christodoulos Patsalides  
Director

Copy to:  
The Audit Committee of Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited)